<DOC>
	<DOC>NCT00692913</DOC>
	<brief_summary>A study designed to see if the study drug will increase blood levels of vitamin D, bone mineral density (BMD), improve biochemical markers of bone turnover, and reduce the number of falls as compared to women receiving standard care for osteoporosis.</brief_summary>
	<brief_title>A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Female 65 years or older Diagnosed with osteoporosis (Bone Mineral Density (BMD) Tscore &lt;= 2.5 at spine or hip) or prior fragility fracture BMD Tscore &lt;=1.5 in at least one of the anatomic sites including lumbar spine, total hip, and femoral neck sites Postmenopausal Low levels of vitamin D as measured 25hydroxyvitamin D Has fallen at least once within the past 12 months Unable to stand or sit upright for at least 30 minutes Has a bone disorder other than osteoporosis Contraindication to the use of FOSAVANCE</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>